Combined Therapeutics

Combined Therapeutics is dedicated to creating safer and more efficacious immunotherapies and vaccines for cancer and infectious diseases. They use their mRNA platform to specifically target therapeutic protein expression, while minimizing off-target effects. Their science involves a therapeutic mRNA modified to include a binding miRNA sequence, encapsulated in a lipid nanoparticle. Advantages of their platform include needing a lower vaccine dose, lengthening vaccine durability, and restricting expression to targeted tissues. Combined Therapeutics was founded in 2016, based in Boston, with international operations in London and Paris.

Jobs: